AMPG 10-Q filed 2026-11-12 | Key takeaways
AMPG filed its 10-Q; prior-period comparison is limited, but the filing discloses During 2026, the company increased investment in dedicated production capacity, strategic inventory, critical-component availability, engineering resources and supply-chain infrastructure ahead of anticipated customer orders. The filing states these initiative.
Key takeaways
Production readiness: The dedicated production line was completed and accepted after September 30, 2026, initial shipments are expected during the fourth quarter of 2026, and $2,640,353 of related deposits are to be reclassified to intangible assets.
Titan APA: Amendment No. 2 reduced the aggregate purchase price by $1,000,000 to $7,000,000 after delivery delays, leaving $1,750,000 of contingent consideration payable when the design-package transfer and manufacturing-partner acknowledgment are completed.
Liquidity: At September 30, 2026, the company had $19,478,374 of cash and cash equivalents, $10,789,959 of marketable securities and $42,142,934 of working capital, while nine-month operating activities used $8,478,749 of cash.
Capital structure: The January rights offering, January registered direct offering and July Series A exercise generated net proceeds of $8,063,498, $8,323,748 and approximately $20,106,334, respectively.
Internal controls: Disclosure controls and internal control over financial reporting remained ineffective because previously disclosed material weaknesses in control documentation, IT general controls and segregation of duties had not been fully remediated.
Customer concentration: The filing provides revenue disaggregation by segment and geography but does not disclose customer percentages of revenue, net sales or accounts receivable.
Comparison context: The supplied prior-quarter and prior-year filings contained no usable source text, so quarter-over-quarter disclosure changes and customer-concentration movements remain unclear.
Key metrics
Disclosure changes
- Strategic Investment in Production Readiness and Supply Chain Resilience
During 2026, the company increased investment in dedicated production capacity, strategic inventory, critical-component availability, engineering resources and supply-chain infrastructure ahead of anticipated customer orders. The filing states these initiatives increased working-capital requirements, operating expenditures and cash utilization, with anticipated revenue benefits targeted for 2027 and 2028 subject to customer orders, production qualification and component availability.
Management links current operating expense and cash use to commercialization spending and states that the anticipated benefits depend on converting customer orders into shipments. - Amendment No. 2 to Titan APA
Amendment No. 2 reduced the Titan asset purchase price from $8,000,000 to $7,000,000 after substantial delivery delays. The contingent liability was reduced to $2,000,000 and then to $1,750,000 after a $250,000 payment; the remaining $750,000 cash and $1,000,000 restricted-stock consideration is payable upon completion of the design-package transfer, which had not occurred as of the report date.
The remaining payment, production-readiness acknowledgment and design-package transfer are conditions to completing the acquired 5G ORAN technology. - Dedicated Production Line and 5G Deployment
After September 30, 2026, the dedicated production line was completed and accepted, with initial shipments expected during the fourth quarter of 2026. The related $2,640,353 deposits are to be reclassified to intangible assets in the fourth quarter and amortized over the remaining useful life of the intellectual property acquired in the Titan transaction.
The filing capitalizes a material deposit and links completion of the production line to expected initial shipments. - Stockholders' Equity — Rights Offerings
During the nine months, the company issued 2,268,204 Units in the January rights offering, 2,230,000 Units in the January registered direct offering and 4,384,163 common shares upon the July Series A exercise. Net proceeds were $8,063,498, $8,323,748 and approximately $20,106,334, respectively, and Series B Rights exercisable at $6.00 remained outstanding through November 20, 2026.
The filing attributes most of the $30,575,276 nine-month financing cash inflow to these equity transactions and related option exercises, while the common-share count increased during the year. - Stock Repurchase Program
The Board authorized the repurchase of up to $10,000,000 of common stock over 24 months on July 7, 2026. The program is non-obligatory, may be suspended, modified or discontinued, and no shares had been repurchased as of the report date.
The authorization creates potential future share repurchases but had not affected share count as of the report date. - Management's Report on Internal Control over Financial Reporting
Management concluded that disclosure controls and internal control over financial reporting were not effective because material weaknesses involving control documentation, IT general controls and segregation-of-duties resources had not been fully remediated. The company reported an enterprise risk register, change-management processes, CEO bank-statement review and continued development of finance, accounting and information-security policies.
The material weaknesses remained in place while the company was increasing production and preparing for larger commercial volumes.
Primary source
TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.
Open SEC filingFollow AMPG in real time
Get material earnings, filing, IR, and earnings-call alerts by email.